JoEllyn McMillan, PhD

Associate ProfessorJoEllyn McMillan

Durham Research Center 3051
985800 Nebraska Medical Center
Omaha, NE 68198-5800

Phone: 402-559-3074
E-mail: JoEllyn McMillan

Keywords: toxicology, environmental, genomics, toxicity mechanisms nanomedicine, drug analysis, cell cultures, antiretroviral drugs, anti-cancer drugs, anti-inflammatory drugs, antimalarial drugs, hemolytic anemia

In the News
Professional Summary

Representative Publications
Dr. McMillan's biographical information

In the news:

UNMC Today | April 28, 2020 
Potential new HIV treatment developed at UNMC 

News Media Roundup: “The World's First HIV Vaccine Mimetic”

UNMC Today | February 6, 2018
Chemically modified drug shows promise for HIV treatment, elimination

College of Public Health - Faculty Highlight

Professional Summary:

My primary role in the Department of Pharmacology and Experimental Neuroscience is in education. My focus in education is two-fold. The first is to develop novel educational methods to assist students in learning basic pharmacological concepts for students in Pharmacy and Allied Health Professions programs. The second is to help provide guided discussions for graduate students in Neuroscience to develop skills to critically evaluate and interpret the literature and to use these skills to formulate new approaches in their scientific investigations.

My research interests have been in the fields of toxicology and development of long-acting drugs for chronic infectious disease such as human immunodeficiency virus. I have used primary liver cells and whole animal rodent models to study mechanisms of liver toxicity of drugs and environmental chemicals such as acetaminophen and trichloroethylene. I have also collaborated with department, UNMC and national investigators with the goal of developing nanoformulations of antiretroviral drugs to provide extended and targeted therapeutic drug concentrations. I have worked with cell culture and animal model systems to understand the pharmacokinetics and pharmacodynamics of long-acting prodrug nanoformulations of existing antiretroviral drugs. 

In the College of Public Health I direct a basic toxicology course for both online and campus-based students in the Masters of Public Health Program. I also direct basic and advanced toxicology courses for students in the Environmental Health and Toxicology Doctoral Program in the Department of Environmental, Agricultural and Occupational Health.

Representative Publications:

  1. Kulkarni TA, Bade AN, Sillman B, Shetty BLD, Wojtkiewicz MS, Gautam N, Hilaire JR, Sravanam S, Szlachetka A, Lamberty BG, Morsey BM, Fox HS, Alnouti Y, McMillan JM, Mosley RL, Meza J, Domanico PL, Yue TY, Moore G, Edagwa BJ, Gendelman HE. 2020. A year-long extended release nanoformulated cabotegravir prodrug. Nature Materials. doi: 10.1038/s41563-020-0674-z. PMID: 32341511 
  2. Sillman B, Bade AN, Dash PK, Bhargavan B, Kocher T, Mathews S, Su H, Kanmogne GD, Poluektova LY, Gorantla S, McMillan J, Gautam N, Alnouti Y, Edagwa B, and Gendelman HE. Creation of a long-acting nanoformulated dolutegravir. Nat. Commun. In Press, 2018.
  3. Kevadiya BD, Woldstad C, Ottemann BM, Dash P, Sajja BR, Lamberty B, Morsey B, Kocher T, Dutta R, Bade AN, Liu Y, Callen SE, Fox HS, Byrareddy SN, McMillan JM, Bronich TK, Edagwa BJ, Boska MD, and Gendelman HE. Multimodal theranostic nanoformulations permit magnetic resonance bioimaging of antiretroviral drug particle tissue-cell biodistribution. Theranostics, 8:256-76, 2018. PMID: 29290806. PMC5743473.
  4. McMillan J, Szlachetka A, Slack L, Sillman B, Lamberty B, Morsey B, Callen S, Gautam N, Alnouti Y, Edagwa B, Gendelman HE, and Fox HS. Pharmacokinetics of a long-acting nanoformulated dolutegravir prodrug in rhesus macaques. Antimicrob. Agents Chemother., 62(1), 2018. PMID: 29061742. PMC5740312.
  5. Zhou T, Su H, Dash P, Lin Z, Dyavar Shetty BL, Kocher T, Szlachetka A, Lamberty B, Fox HS, Poluektova L, Gorantla S, McMillan J, Gautam N, Mosley RL, Alnouti Y, Edagwa B, and Gendelman HE. Creation of a nanoformulated cabotegravir prodrug with improved antiretroviral profiles. Biomaterials, 151:53-65, 2018. PMID: 29059541.
  6. Gnanadhas DP, Dash PK, Sillman B, Bade AN, Lin Z, Palandri DL, Gautam N, Alnouti Y, Gelbard HA, McMillan J, Mosley RL, Edagwa B, Gendelman HE, and Gorantla S. Autophagy facilitates macrophage depots of sustained release nanoformulated antiretroviral drugs. J. Clin. Invest. 127(3):857-873, 2017. PMID: 28134625
  7. Edagwa B, McMillan J, Sillman B, and Gendelman HE. Long-acting slow effective release antiretroviral therapy. Expert Opin Drug Deliv. 6:1-11, 2017. PMID: 28128004
  8. Kevadiya BD, Bade AN, Woldstad C, Edagwa BJ, McMillan JM, Sajja BR, Boska MD, and Gendelman HE. Development of europium doped core-shell silica cobalt ferrite functionalized nanoparticles for magnetic resonance imaging. Acta Biomaterialia. 49:507-520, 2017. PMID: 27916740
  9. Shahnaz G, Edagwa BJ, McMillan J, Akhtar S, Raza A, Qureshi NA, Yasinzai M, Gendelman HE. Development of mannose-anchored thiolated amphotericin B nanocarriers for treatment of visceral leishmaniasis. Nanomedicine (Lond). 12(2):99-115, 2017. PMID: 27879160. PMCID: PMC5144491
  10. Guo D, Zhou T, Arainga M, Palandri D, Gautam N, Bronich T, Alnouti Y, McMillan J, Edagwa B, and Gendelman HE. Creation of a long-acting nanoformulated 2’,3’-dideoxy-3’-thiacytidine. JAIDS, 74(3):e75-e83, 2017. PMID: 27559685. PMCID: PMC5305294 
  11. Singh D, McMillan J, Hilaire J, Gautam N, Palandri D, Alnouti Y, Gendelman HE, and Edagwa B. Development and characterization of a long-acting nanoformulated abacavir prodrug. Nanomedicine (Lond), 11(15): 1913-1927, 2016. PMID: 27456759
  12. Martinez-Skinner AL, Araínga MA, Puligujja P, Palandri DL, Baldridge HM, Edagwa BJ, McMillan JM*, Mosley RL, and Gendelman HE. Cellular Responses and Tissue Depots for Nanoformulated Antiretroviral Therapy. 2015; PLoS One, 10(12):e0145966.PMID: 26716700. PMCID: PMC4696780.
  13. Puligujja P, Arainga M, Dash P, Palandri D, Mosley RL, Gorantla S, Poluektova L, McMillan J, and Gendelman HE. Pharmacodynamics of folic acid-receptor targeted antiretroviral nanotherapy in HIV-1-infected humanized mice. Antiviral Res., 120: 85-88, 2015. PMID: 26026666.

Additional publications in PubMed.

Dr. McMillan's biographical information
Top of page